Advertisement

Amyloid-Targeted Alzheimer's Drugs Don't Improve Cognition in Two Sets of Trials — Physician’s First Watch

Medical News |
January 23, 2014

Amyloid-Targeted Alzheimer's Drugs Don't Improve Cognition in Two Sets of Trials

By Joe Elia

Two monoclonal antibodies designed to lessen amyloid-beta deposition in patients with Alzheimer disease fail to produce meaningful clinical results, according to studies in the New England Journal of Medicine.

One drug, bapineuzumab, was tested in 2450 patients with mild-to-moderate disease during two trials. Patients were randomized to active treatment or placebo every 13 weeks. At the 78-week mark, cognitive and disability scores did not differ between the groups. Findings were similar for carriers and noncarriers of an apolipoprotein E variant.

The other monoclonal antibody, solanezumab, was similarly tested in two trials among some 2000 patients with mild-to-moderate Alzheimer's. Here too, solanezumab failed to distinguish itself from placebo in cognitive and disability scores by trial's end at 80 weeks.

Despite these results, editorialists advocate continuing to pursue therapies based on the "amyloid hypothesis" while "accepting that we lack clarity on the roles that different forms of [amyloid-beta] play in the disease."

Reader Comments (2)

Shirley Svihra, MLS Other, Other, retired

Excellent summary of test results for new Alzheimer's drugs

Wd xie

Anyone come cross noticed a small molecule can inhibit Al progress in preclinical ?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement